pharma · Uveal Melanoma · HLA-A2 negative metastatic uveal melanoma · IDYA
IDEAYA Biosciences
IDEAYA Biosciences is a pharma organization headquartered in South San Francisco, USA. It trades on NYSE under ticker IDYA. Primary therapeutic focus areas include Uveal Melanoma, HLA-A2 negative metastatic uveal melanom
5000 Shoreline Ct, Suite 300, South San Francisco, California 94080, US HQ
2015 Founded
248 Employees
Public company Type
IDYA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 5000 Shoreline Ct, Suite 300, South San Francisco, California 94080, US
- Founded
- 2015
- Employees
- 248
- Programs
- 14
- Drugs
- 12
- Patents
- 12
IDE397-001
Phase 1 · other · Advanced Solid Tumors
IDE397-001 for Advanced Solid Tumors is a Phase 1 program (other) at IDEAYA Biosciences with 1 ClinicalTrials.gov record(s).
Internal code IDE397-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- IDEAYA Biosciences
- Phase
- Phase 1
- Modality
- other
- Indication
- Advanced Solid Tumors
- Status
- active
- Trials
- 1